{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:46:58Z","timestamp":1789537618576,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jhep.2026.06.022","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:50:48Z","timestamp":1782143448000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials"],"prefix":"10.1016","author":[{"given":"Merve","family":"Rousian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-0104","authenticated-orcid":false,"given":"Remo","family":"Alessandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Schleimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-8054","authenticated-orcid":false,"given":"Ghassan","family":"Abou-Alfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4115-2200","authenticated-orcid":false,"given":"Neeta","family":"Vachharajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majella","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wills","family":"Filipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Buisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5193-0820","authenticated-orcid":false,"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Homs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Doukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britte ten","family":"Haaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger-Jan","family":"Swijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-1823","authenticated-orcid":false,"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Hagendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4688-2921","authenticated-orcid":false,"given":"Nadia Haj","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3114-8521","authenticated-orcid":false,"given":"Francesco Enrico","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-017X","authenticated-orcid":false,"given":"Kevin","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3359-3186","authenticated-orcid":false,"given":"Peter","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"D'Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"G\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Kemeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1635-5768","authenticated-orcid":false,"given":"William","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas Groot","family":"Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jhep.2026.06.022_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.hpb.2023.06.019","article-title":"Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma","volume":"25","author":"Olthof","year":"2023","journal-title":"HPB (Oxford)"},{"issue":"4","key":"10.1016\/j.jhep.2026.06.022_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1072-7515(01)01016-X","article-title":"Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes","volume":"193","author":"Weber","year":"2001","journal-title":"J Am Coll Surg"},{"issue":"12","key":"10.1016\/j.jhep.2026.06.022_bib3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/archsurg.2012.1962","article-title":"Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients","volume":"147","author":"Ribero","year":"2012","journal-title":"Arch Surg"},{"issue":"2","key":"10.1016\/j.jhep.2026.06.022_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jamcollsurg.2015.04.009","article-title":"Outcomes after resection of intrahepatic cholangiocarcinoma: external validation and comparison of prognostic models","volume":"221","author":"Doussot","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"5","key":"10.1016\/j.jhep.2026.06.022_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.21037\/jgo.2017.11.06","article-title":"Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States","volume":"9","author":"Altman","year":"2018","journal-title":"J Gastrointest Oncol"},{"issue":"7","key":"10.1016\/j.jhep.2026.06.022_bib6","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","article-title":"Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival","volume":"43","author":"Wu","year":"2019","journal-title":"World J Surg"},{"issue":"14","key":"10.1016\/j.jhep.2026.06.022_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jhep.2026.06.022_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.jhep.2026.06.022_bib9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jhep.2026.06.022_bib10","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/cncr.30488","article-title":"Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients","volume":"123","author":"Yamashita","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jhep.2026.06.022_bib11","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","article-title":"Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival","volume":"20","author":"Jarnagin","year":"2009","journal-title":"Ann Oncol"},{"issue":"3\u20134","key":"10.1016\/j.jhep.2026.06.022_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000324704","article-title":"Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?","volume":"80","author":"Kemeny","year":"2011","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.jhep.2026.06.022_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.06.022_bib14","article-title":"Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma-PUMP-2 trial","author":"Franssen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.06.022_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","article-title":"Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases","volume":"201","author":"Allen","year":"2005","journal-title":"J Am Coll Surg"},{"issue":"11 Pt 1","key":"10.1016\/j.jhep.2026.06.022_bib16","first-page":"3784","article-title":"A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil","volume":"38","author":"Ensminger","year":"1978","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jhep.2026.06.022_bib17","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2026.06.022_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102258","article-title":"Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis","volume":"99","author":"Edeline","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.jhep.2026.06.022_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29824","article-title":"Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone","volume":"122","author":"Konstantinidis","year":"2016","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jhep.2026.06.022_bib20","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1245\/s10434-022-11439-x","article-title":"Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"29","author":"Holster","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2026.06.022_bib21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.06.022_bib22","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"15","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.022_bib23","doi-asserted-by":"crossref","unstructured":"Finn RS, Ueno M, Yoo C, et al. Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC). Chicago, IL, & online: presented at 2024 ASCO Annual Meeting; abstract 4093.","DOI":"10.1200\/JCO.2024.42.16_suppl.4093"},{"issue":"5","key":"10.1016\/j.jhep.2026.06.022_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2026.06.022_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [published correction appears in Lancet Oncol. 2024 Jan;25(1):e3. doi: 10.1016\/S1470-2045(23)00642-3.]","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jhep.2026.06.022_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jhep.2026.06.022_bib27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jhep.2026.06.022_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.jhep.2026.06.022_bib29","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.jhep.2026.06.022_bib30","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1002\/cncr.29619","article-title":"Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?","volume":"121","author":"Spolverato","year":"2015","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2026.06.022_bib31","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma: what percentage of patients are eligible?","volume":"26","author":"Schleimer","year":"2024","journal-title":"HPB"},{"issue":"1","key":"10.1016\/j.jhep.2026.06.022_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/HEP.0000000000000544","article-title":"Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials","volume":"79","author":"Edeline","year":"2024","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2026.06.022_bib33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jhep.2026.06.022_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO-25-02119","article-title":"All things excellent are as difficult as they are rare","volume":"44","author":"Mayo","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.06.022_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826026553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826026553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:39:54Z","timestamp":1784666394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826026553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"alternative-id":["S0168827826026553"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.022","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}